Skip to main content
Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
17.87
+0.68 (3.96%)
At close: Dec 5, 2025, 4:00 PM EST
17.88
+0.01 (0.06%)
After-hours: Dec 5, 2025, 7:25 PM EST

Mesoblast Revenue

In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth. Mesoblast had revenue of $14.04M in the half year ending June 30, 2025, with 244.25% growth.

Revenue (ttm)
$17.20M
Revenue Growth
+191.39%
P/S Ratio
131.59
Revenue / Employee
$212,321
Employees
81
Market Cap
2.26B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Jun 30, 202517.20M11.30M191.39%
Jun 30, 20245.90M-1.60M-21.32%
Jun 30, 20237.50M-2.71M-26.54%
Jun 30, 202210.21M2.78M37.36%
Jun 30, 20217.43M-24.72M-76.88%
Jun 30, 2020 Pro Pro Pro
Jun 30, 2019 Pro Pro Pro
Jun 30, 2018 Pro Pro Pro
Jun 30, 2017 Pro Pro Pro
Jun 30, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 435.16B
Johnson & Johnson 92.15B
Merck & Co. 64.24B
AbbVie 59.64B
Eli Lilly and Company 59.42B
AstraZeneca 58.13B
Novartis AG 56.37B
Novo Nordisk 49.58B
Revenue Rankings

MESO News

More News